Activated neutrophils release a neutrophil serine proteinase (NSP) called Proteinase 3 (PR3). In granulomatosis with polyangiitis (GPA), an autoimmune vasculitis, enhanced PR3 release results in endothelial damage. Serine proteinase inhibitors (serpins) such as α-1 proteinase inhibitor (API) inhibit NSPs through the serpin’s reactive center loop (RCL). However, API is known to bind PR3 with a low specificity, compared to its main inhibitory target Human Neutrophil Elastase (HNE). The current treatment for GPA is immunosuppression, which leaves patients immunocompromised. Thus, the overall aim of this study was to engineer an API variant with a higher specificity to PR3 than HNE, which could serve as a possible novel therapeutic strategy for GPA. We created an API expression library, hypervariable at RCL residues A355-I356-P357-M358-S359, and expressed it in a T7 bacteriophage display system. This phage library was then biopanned for PR3 binding. Two conditions were used for each round of biopanning: experimental, with PR3, and the negative control, without PR3. The library was biopanned for a total of five consecutive rounds, with the product of one screen serving as the starting material for the next. A bacterial mass lysate screen was also employed to further probe the library with PR3. The phage-display and bacterial lysate screens resulted in the selection of two novel variants API-DA (D357/A358) and API-N (N359). Serpin-proteinase gel complexing assays indicated that API-N formed complex with PR3 similar to API-WT (wild-type), while API-DA was mainly cleaved as a substrate. There was no significant difference between the second order rate constants of API-N and API-WT reactions with PR3. Rate constants for API-DA binding to PR3 or for API-HNE reactions were not completed due to novel coronavirus (COVID-19) restrictions. However, this project successfully demonstrated the ability to screen a hypervariable API phage library with PR3, yielding two new novel API variants. / Thesis / Master of Science in Medical Sciences (MSMS) / When harmful substances enter our body such as bacteria or viruses, we have ways of protecting ourselves from them. One of those ways is through a cell called the neutrophil. This is an immune cell that can release “fighting tools” into our blood to combat the harm. Some of these tools are called proteins. One of those proteins is Proteinase 3. However, sometimes our neutrophils can be activated without the presence of viruses or bacteria by products made in our bodies called autoantibodies. When this happens, too many of the “fighting tool” Proteinase 3 is released leading to damage to the tubes or vessels that our blood flows through. This project aimed to find a new possible way to stop these extra fighting tools from doing harm to our body. We did this by creating a library of different proteins that can stop Proteinase 3 once it is released by the neutrophil.

Polyclonal antibodies against the first two enzymes of the Arabidopsis thaliana flavonoid biosynthetic pathway were developed using conventional and phage antibody technology. cDNAs from Arabidopsis coding regions of chalcone synthase (CHS) and chalcone isomerase (CHI) were sub-cloned in frame into a bacterial expression vector as fusions with glutathione Stransferase (GST) using standard directional cloning techniques. Analysis of crude extracts of Escherichia coli containing GST .. CHS or GST .. CHI fusion protein indicated that the cells expressed equivalent amounts per volume of culture. CHS and CHI were purified to near homogeneity, yielding approximately 100 micrograms of GST .. CHS and 1 milligram of GST-CHI per liter of culture. The purified fusion proteins were injected into chickens and polyclonal lgY·s were purified from egg yolk Accumulation of CHS and CHI, as well as products of the pathway, were compared during the first eight days of Arabidopsis development. CHS and CHI are sequentially induced and reach maximal accumulation levels by day 5. Anthocyanidin levels are offset by one reaching maximal levels at day 6. The fusion proteins were also used to screen a phage-display library for Fabl fragments that recognize CHS and CHI epitopes. Preliminary data indicated that enrichment of phage displaying antibodies against CHS and CHI was successful. Phage-derived antibodies against CHS and CHI provide valuable tools for future experiments addressing Western blot analysis, immunolocalization experiments, and disruption of the flavonoid biosynthetic pathway by introduction of the corresponding genes into transgenic Arabidopsis plants. / Master of Science

Interés del estudio La adhesión a la mucosa y epitelio intestinal constituye una importante característica de los probióticos que condiciona su permanencia en el intestino y su capacidad de interactuar con el huésped. Sin embargo, la información sobre este proceso a nivel molecular es escasa. Objetivos Se abordó la caracterización de la capacidad de adhesión de una colección de cepas de la especie Lactobacillus casei, de diferentes orígenes, sobre proteínas que forman la matriz extracelular y se aplicaron diferentes técnicas analíticas para identificar factores proteicos implicados en la adhesión en una cepa modelo de L. casei. Elementos de la metodología a destacar La metodología incluye el análisis in silico de la presencia de factores de adhesión, la obtención de mutantes en L. casei y su caracterización fenotípica en adhesión a proteínas y a líneas celulares, la identificación de factores de superficie con capacidad de adhesión por espectrometría de masas y phage display y la caracterización de la adhesión de estos purificados de manera recombinante. Resultados logrados Se ha determinado que la capacidad de adhesión es multifactorial, con un componente mayoritario proteico, no existiendo relación con el origen de la cepa. Se han identificado varias proteínas de L. casei con capacidad de adhesión. Entre ellas cabe destacar proteínas de localización primaria citoplásmática (p.ej. enolasa y gliceraldehído-3-fosfato deshidrogenasa) que se encuentran expuestas en superficie y presentan capacidad adhesiva. Se ha caracterizado la presencia en superficie de L. casei de proteínas ancladas covalentemente por mecanismo dependiente de enzimas sortasa. Se han identificado las sortasas presentes en L. casei y su papel en la adhesión se ha evaluado mediante la construcción de mutantes, comprobándose que parte de ellas juegan un papel en ésta. I / Muñoz Provencio, D. (2011). Caracterización de factores de adhesión a proteínas de la matriz extracelular en Lactobacillus casei [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/14013

付記する学位プログラム名: 京都大学卓越大学院プログラム「メディカルイノベーション大学院プログラム」 / 京都大学 / 新制・課程博士 / 博士(薬科学) / 甲第25227号 / 薬科博第189号 / 新制||薬科||21(附属図書館) / 京都大学大学院薬学研究科医薬創成情報科学専攻 / (主査)教授 大野 浩章, 教授 二木 史朗, 教授 掛谷 秀昭 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

Thesis advisor: Jianmin Gao / Covalent drugs present a unique situation in the clinical world. Formation of a covalent bond between a drug molecule and its target protein can lead to significant increases in a number of desirable traits such as residence time, potency, and efficacy of a drug. From a kinetic perspective, the formation of a covalent bond between a drug and its target functionally eliminates the dissociation rate (koff) of the compound, ensuring that the compound will stay engaged with its target. However, development of covalent drugs has been met with caution and concern, as an irreversible covalent bond forming on the wrong target can have disastrous results, so specificity is of the utmost importance. One option for increasing specificity is by linking a covalent binding electrophile, or warhead, to a peptide. Peptide-based therapeutics have already been shown to serve as effective protein-targeting modalities with high specificity, a specificity that would greatly benefit covalent drugs. Phage display is a powerful technique for the discovery of selective peptides which utilizes the screening of vast libraries of randomized peptides to identify strong binders. This technology has been used to discover a large number of protein-targeting peptides, but also a smaller number of cyclic, covalent binding peptides that function as enzymatic inhibitors. Herein, this study aimed to explore the idea of adding covalent-binding functionality to phage libraries in novel ways and expand upon the scope of proteins that can be targeted with phage libraries containing covalent libraries. We sought to develop a mechanistic and chemical understanding of the interactions between bacteriophage and chemical warheads to best understand both the limits and the potential of this technology. In order to best understand the relationship between chemical warhead and phage particle, a model system was developed based on the M13KE pIII protein. It was found that the extracellular N-terminal domains of this protein could be expressed and purified in low yields in bacterial cells and that these domains would behave similarly in solution as in the membrane of the M13KE bacteriophage. With this protein in hand, experiments previously performed using small, cysteine containing peptides, could be performed on a full protein to mimic the phage labeling environment. This protein was used to identify efficient cysteine crosslinkers, most notably dichloroacetone (DCA) and bis-chlorooxime (BCO). The pIII protein system was then used to study the viability of bifunctional warhead molecules containing a covalent warhead and a cysteine crosslinker. Based on preliminary analyses with the pIII protein, aryl sulfonyl fluoride was chosen as a novel warhead candidate that warranted further pursuit. Kinetic NMR studies verified that aryl sulfonyl fluoride was capable of forming covalent bonds with phenols under phage labeling conditions. Labeling experiments analyzed with LC/MS seemed to indicate a degradation of the warhead. However, as the source of the degradation was not able to be determined, it was decided that various affinity assays would be used to identify if phage could be labeled with an aryl sulfonyl fluoride-DCA conjugate. Both streptavidin-bead pulldown assays and ELISA assays were used, however both assays yielded results that could not conclusively verify the integrity of the warhead. During phage labeling experiments, a phenomenon was noted that phage titers after modification showed a 2-3 order of magnitude drop in phage count. Covalent modification of phage beyond what is intended could have troubling consequences for all covalent phage libraries, and so a more in-depth approach was taken to identify and better understand phage toxicity as it relates to covalent warheads. As a model, a well-studied diazaborine-mediated warhead with a slow dissociation rate was selected and used in a range of phage toxicity screenings. Despite statistical fluctuations between trials, toxicity screenings using this warhead served to highlight a unique concern for bifunctional covalent warheads. A concentration-dependent toxicity can be seen in phage incubated with bifunctional small molecules that is not present when incubated with the monofunctional equivalents. The presence of this toxicity even towards a phage with no free thiols highlights a unique challenge of off-target labeling within phage particles that, if solved, could provide the next significant step towards developing novel covalent phage libraries. / Thesis (MS) — Boston College, 2022. / Submitted to: Boston College. Graduate School of Arts and Sciences. / Discipline: Chemistry.

Lorsqu’il est surexprimé ou activé constitutivement par mutation, le récepteur tyrosine kinase KIT est impliqué dans le développement de pathologies prolifératives comme les mastocytoses, les tumeurs stromales gastro-intestinales (GIST) et certaines leucémies. La voie de signalisation KIT représente donc une cible thérapeutique majeure en oncologie. Le développement d’une nouvelle classe de molécules pharmacologiques appelées inhibiteurs de tyrosine kinase (ITK) est en plein essor. Un exemple majeur d’ITK est l’imatinib qui cible, entre autre, KIT et est efficace dans la plupart des GIST. Cependant, le traitement aux ITK est souvent confronté au phénomène de résistance primaire ou acquise par mutation secondaire. C’est pourquoi nous cherchons à développer de nouveaux composés ciblant KIT ou les voies de transductions activées par ses formes oncogéniques, et ce par 3 approches.Nous avons récemment montré que les mutants oncogéniques de KIT ont une localisation intracellulaire alors que KIT sauvage est exprimé à la membrane. L’inhibition de l’activité kinase des mutants restaure une localisation normale. A partir de cette observation, nous avons créé et validé un test de criblage par cytométrie mesurant la relocalisation de KIT muté à la surface cellulaire. Le criblage d’une chimiothèque nous a permis de sélectionner de nouveaux inhibiteurs de la signalisation KIT actifs sur des lignées cellulaires mutées pour KIT.Nous avons utilisé la technique du phage display pour sélectionner des anticorps au format scFv et VHH spécifiques de la partie intracellulaire de KIT mutant. Lors de leur expression dans le cytosol (on parle alors d’intrabodies), leur fixation au niveau de KIT inhibe soit directement l’activité kinase, soit le recrutement de partenaires de signalisation. Nous avons obtenu des intrabodies de différentes spécificités vis-à-vis des formes de KIT dont la caractérisation fonctionnelle est en cours Les intrabodies inhibiteurs seront utilisés pour cribler des chimiothèques par ELISA. Les molécules chimiques recherchées empêcheront la fixation des intrabodies sur la région intracellulaire de KIT. On sélectionnera donc des molécules inhibant potentiellement l’oncogénicité de KIT.Nous avons développé des anticorps au format scFv-Fc par phage display qui reconnaissent le domaine extracellulaire de KIT. Deux des anticorps sélectionnés inhibent donc la signalisation induite par le SCF. Dans des lignées de leucémie exprimant KIT WT, nous avons montré que l’utilisation de ces anticorps entraîne une diminution de la viabilité cellulaire. De plus, ils diminuent également la prolifération de lignées de leucémie à mastocytes sensibles et résistantes à l’imatinib (HMC11 et HMC12, respectivement). Ils représentent donc des outils thérapeutiques potentiels pour le traitement des pathologies impliquant KIT ainsi que pour contourner la résistance aux ITK de certains mutants. / When overexpressed or constitutively active by mutation, the tyrosine kinase receptor KIT is involved in some proliferative diseases such as gastro-intestinal stromal tumors (GIST), mastocytosis and some leukemia. Therefore, KIT signaling represents a major target in oncology. Development of a new therapeutic class called tyrosine kinase inhibitors is in full expansion. A major example of TKI is imatinib which targets KIT and is efficient in the majority of GIST cases. However, TKI treatment is often unpaired by primary or acquired resistance due to secondary mutations. That is why we aim to develop new compounds to target KIT or associated signaling pathways by three strategies.We have recently shown that oncogenic KIT mutants are intracellularely localized whereas WT KIT is expressed at the cell surface. Kinase activity inhibition leads to membrane mutants’ relocalization. Based on this finding, we developed and validated a screening assay measuring mutants’ relocalization by cytometry. Chemicals library screening allows us to select new KIT signaling inhibitors active on KIT mutant cell lines.We used phage display to generate scFv and VHH antibodies which are specific to KIT intracellular domain. When expressed in cytoplasm (they are called intrabodies), their binding on KIT inhibits kinase activity directly or signaling partners’ recruitment. Selected intrabodies are specific to various KIT isoforms and their functional characterization is ongoing. KIT inhibitory intrabodies will be used to screen chemical libraries by ELISA for drugs that block intrabodies binding on KIT intracellular domain. We will then select molecules that potentially inhibit KIT oncogenicity.We developed scFv-Fc antibodies by phage display that recognize KIT extracellular domain. Two selected antibodies inhibit SCF induced signaling. In WT KIT expressing leukemic cell lines, we showed that antibody treatment reduces cell viability. Moreover, they also diminish cell proliferation of 2 imatinib sensitive and resistant mast cell leukemia cell lines (HMC1.1 and HMC1.2, respectively). They represent potential therapeutic tools for treatment of KIT involved diseases and for bypass TKI resistance of some mutants.

Mon travail de thèse a porté sur le ciblage de la vascularisation tumorale : des molécules ciblant l'endothélium tumoral ont été recherchées dans le but d'amener des molécules thérapeutiques spécifiquement vers l'endothélium tumoral afin de le détruire et d'atteindre la tumeur qui en dépendait. D'après les données de la littérature, deux cibles ont été choisies pour notre étude : la sélectine E et l'endogline. La sélectine E est une glycoprotéine surexprimée à la surface de l'endothélium activé des zones inflammatoires et tumorales. Classiquement, des antagonistes de son ligand naturel, le SleX, sont recherchés. En nous appuyant sur les groupements clés de l'interaction entre la sélectine E et le SleX, plusieurs familles de mimes du SleX ont été élaborées. La capacité de ces mimes à déplacer l'interaction du SleX exprimé à la surface des cellules HL-60 avec la sélectine E a été évaluée dans un test d'adhésion. Cependant, aucun des mimes testés n'a présenté une affinité suffisante pour envisager son utilisation comme tête de ciblage. Une deuxième stratégie a consisté à rechercher des ligands peptidiques de la sélectine E en criblant des HUVECs activées avec une banque de peptides sur phages. Plusieurs phages-peptides testés en ELISA ont montré une meilleure affinité pour la sélectine E et / ou avec la sélectine P par rapport au phage sans insert. Des tests de compétition avec des peptides synthétiques correspondants permettront d'évaluer leur spécificité pour la cible. En ce qui concerne l'endogline, des ligands peptidiques ont été recherchés avec une banque de peptides sur phages. Dans un premier temps, le gène codant l'endogline humaine a été cloné dans un vecteur d'expression eucaryote afin de réaliser la sélection sur la protéine cellulaire. Une sélection sur la protéine recombinante a été réalisée par la suite pour diminuer le bruit de fond lié aux cellules. Parmi les peptides obtenus, certains ont montré des homologies de séquence avec des ligands de l'endogline et le test de ces phages-peptides en ELISA sur la protéine recombinante a donné un fort signal par rapport au phage sans insert. Ces peptides seront caractérisés prochainement. En conclusion, des ligands peptidiques des sélectines E et P et de l'endogline ont peut-être été identifiés. Ce travail a par ailleurs permis de mettre en place les outils nécessaires à l'utilisation de la technologie de sélection avec des banques de peptides sur phages dans les meilleures conditions possibles.

Protein engineering and in vitro selection systems are powerful methods to generate binding proteins. In nature, antibodies are the primary affinity proteins and their usefulness has led to a widespread use both in basic and applied research. By means of combinatorial protein engineering and protein library technology, smaller antibody fragments or alternative non-immunoglobulin protein scaffolds can be engineered for various functions based on molecular recognition. In this thesis, a 46 amino acid small albumin-binding domain derived from streptococcal protein G was evaluated as a scaffold for the generation of affinity proteins. Using protein engineering, the albumin binding has been complemented with a new binding interface localized to the opposite surface of this three-helical bundle domain. By using in vitro selection from a combinatorial library, bispecific protein domains with ability to recognize several different target proteins were generated. In paper I, a bispecific albumin-binding domain was selected by phage display and utilized as a purification tag for highly efficient affinity purification of fusion proteins. The results in paper II show how protein engineering, in vitro display and multi-parameter fluorescence-activated cell sorting can be used to accomplish the challenging task of incorporating two high affinity binding-sites, for albumin and tumor necrosis factor-alpha, into this new bispecific protein scaffold. Moreover, the native ability of this domain to bind serum albumin provides a useful characteristic that can be used to extend the plasma half-lives of proteins fused to it or potentially of the domain itself. When combined with a second targeting ability, a new molecular format with potential use in therapeutic applications is provided. The engineered binding proteins generated against the epidermal growth factor receptors 2 and 3 in papers III and IV are aimed in this direction. Over-expression of these receptors is associated with the development and progression of various cancers, and both are well-validated targets for therapy. Small bispecific binding proteins based on the albumin-binding domain could potentially contribute to this field. The new alternative protein scaffold described in this thesis is one of the smallest structured affinity proteins reported. The bispecific nature, with an inherent ability of the same domain to bind to serum albumin, is unique for this scaffold. These non-immunoglobulin binding proteins may provide several advantages as compared to antibodies in several applications, particularly when a small size and an extended half-life are of key importance. / <p>QC 20121122</p>

The family 1 cellulose-binding modules (CBM1) form a groupof small, stable carbohydrate-binding proteins. These modulesare essential for fungal cellulosedegradation. This thesisdescribes both functional studies of the CBM1s as well asprotein engineering of the modules for several objectives. The characteristics and specificity of CBM1s from theTrichoderma reeseiCel7A and Cel6A, along with severalother wild type and mutated CBMs, were studied using bindingexperiments and transmission electron microscopy (TEM). Datafrom the binding studies confirmed that the presence of onetryptophan residue on the CBM1 binding face enhances itsbinding to crystalline cellulose. The twoT. reeseiCBM1s as well as the CBM3 from theClostridium thermocellumCipA were investigated by TEMexperiments. All three CBMs were found to bind in lineararrangements along the sides of the fibrils. Further analysesof the bound CBMs indicated that the CBMs bind to the exposedhydrophobic surfaces, the so called (200) crystalline face ofValoniacellulose crystals. The function and specificity of CBM1s as a part of an intactenzyme were studied by replacing the CBM from the exo-actingCel7A by the CBM1 from the endoglucanase Cel7B. Apart fromslightly improved affinity of the hybrid enzyme, the moduleexchange did not significantly influence the function of theCel7A. This indicates that the two CBM1s are analogous in theirbinding properties and function during cellulosehydrolysis. The CBM1 was also used for immobilization studies. Toimprove heterologous expression of a CBM1-lipase fusionprotein, a linker stability study was carried out inPichia pastoris. A proline/threonine rich linker peptidewas found to be stable for protein production in this host. Forwhole bacterial cell immobilization, theT. reeseiCel6A CBM1 was expressed on the surface of thegram-positive bacteria,Staphylococcus carnosus. The engineeredS. carnosuscells were shown to bind cellulosefibers. To exploit the stable CBM1 fold as a starting point forgenerating novel binders, a phage display library wasconstructed. Binding proteins against an amylase as well asagainst a metal ion were selected from the library. Theamylase-binding proteins were found to bind and inhibit thetarget enzyme. The metal binding proteins selected from thelibrary were cloned on the surface of theS. carnosusand clearly enhanced the metal bindingability of the engineered bacteria. <b>Keywords</b>: cellulose-binding, family 1carbohydrate-binding module, phage display, bacterial surfacedisplay, combinatorial protein library, metal binding, proteinengineering,Trichoderma reesei, Staphyloccus carnosus.

Ce mémoire de thèse présente mes travaux sur la détermination de la susceptibilité et de la résistance des intégrases (INs) du virus de l'immunodéficience humaine (VIH) aux inhibiteurs de transfert de brins de l'IN (INSTIs) ainsi que le développement de fragments d'anticorps simple-chaîne (sdAbs) ciblant l'IN du VIH. Tout d'abord, car les études antérieures ont suggéré que les variations significatives de l'IN de souche CRF02_AG pourrait avoir des effets consécutifs sur l'interaction entre l'inhibiteur et l'IN, la susceptibilité de l'IN de souche CRF02_AG du VIH-1 aux dernières INSTIs a été déterminée. Accord avec l'étude in silico, nous avons mis en évidence que l'activité de 3'-processing et de transfert de brin des INs de souche B et de souche CRF02_AG sont comparables. La susceptibilité des INs recombinantes de souche CRF02_AG aux INSTIs utilisés (Raltégravir-RAL, Elevitégravir-EVG et L-731, 988) est similaire à celle de l'IN de souche B, malgré les variations naturelles qui se produisent dans les INs de souche CRF02_AG. Le polymorphisme de l'IN de CRF02_AG n'a pas d'effet significatif sur la susceptibilité aux INSTIs. Dans un second temps, la résistance de l'IN du VIH-2 au RAL, l'unique INSTI approuvé, a été confirmée in vitro avec des enzymes mutées portant des mutations de résistance. Les mutations aux positions 155 et 148 jouent un rôle similaire pour les VIH-1 et VIH-2, en rendant l'IN résistante au RAL. La mutation G140S confère peu de résistance, mais compense le défaut catalytique dû à la mutation Q148R. À l'inverse, Y143C seule ne confère pas de résistance au RAL excepté si la mutation E92Q est également présente. De plus, l'introduction de la mutation Y143C dans le mutant résistant N155H baisse le niveau de résistance de l'enzyme contenant la mutation N155H, ce qui pourrait expliquer l'absence de détection de ces deux mutations ensemble dans un seul génome. Enfin, des anti-VIH sdAbs avec nombreuses propriétés intéressantes ont été sélectionnés pour développer des agents antirétroviraux. Après la sélection de sdAb ciblant l'IN du VIH, nous avons obtenu des qui sdAbs qui reconnaissent spécifiquement une vaste gamme d'INs in vitro, y compris le mutant G140S/Q148R résistant aux INSTIs. Néanmoins, l'activité inhibitrice des sdAbs n'a pas été observée. Les sdAbs ciblant l'IN du VIH peuvent être utilisés pour d'autres applications, telles que des réactifs ciblant des nanocapteurs. À l'avenir, en raison des avantages uniques des sdAbs, le développement de sdAbs anti-IN du VIH qui bloquent la réplication du VIH reste attractive pour l'obtenir des inhibiteurs efficaces de l'IN.